Dr. Ravi Salgia is an expert in thoracic oncology. He has clinical expertise in thoracic oncology, and has developed a strong program in novel therapeutics targeting thoracic malignancies. He has been practicing medical oncology with special expertise in thoracic oncology for more than 15 years. Dr. Salgia also consults on national and international cases in thoracic malignancies.

He has defined several novel targets in oncology, and leads a strong clinical and research group. Dr. Salgia is developing potential biomarkers that would be useful for early diagnosis, linkage to prognosis, and therapeutic monitoring in these diseases.

His research includes studying targeted therapies that enhance the quality of life for patients with cancer. Specifically, he and his laboratory identified that targeting the receptor tyrosine kinases are important in lung cancer. Most recently, they identified unique mutations of the receptor tyrosine kinase c-Met. In addition, they have discovered important pathways in heat shock proteins. Dr. Salgia's clinical and research effort is to bring these advanced therapies for patient benefit. His work has been funded by the American Cancer Society, the National Cancer Institute, MARF, and the University of Chicago Research Cancer Center.

Dr. Salgia has published numerous articles in prestigious journals, and has contributed to books related to thoracic malignancies. He is also an associate editor for various journals, and consults in thoracic oncology for Best Doctors.